Xiuzheng Pharmaceutical's revenue tops 70 billion yuan for the first time, while general manager Xiu Jie is hit with a consumption restriction

罚决定··CN·Read original
2▲0 ▼0Impact / 5
Summary · why it matters

The 2026 list of China's top 500 private enterprises has been released. Xiuzheng Pharmaceutical Group ranked 162nd with operating revenue of 71.202 billion yuan, making it the only company from Jilin Province on the list and marking the first time in nearly a decade that its revenue has exceeded 70 billion yuan. However, the group's average annual compound growth rate over the past ten years was only 2.16 percent, and its ranking has fallen from 53rd on the 2016 list to outside the top 150. According to a review by Caizhongshe, between June 22 and August 5, 2026, the group's core entity and three affiliated companies were subject to enforcement filings by courts in four locations, with total enforcement targets amounting to 97.3039 million yuan. Among them, the affiliated company Jilin Xiujiantang Health Technology Co., Ltd. had a single target of 92.6 million yuan. In August 2026, the Gongshu District People's Court in Hangzhou issued a consumption restriction order against Xiuzheng Pharmaceutical Group Co., Ltd. due to a capital contribution dispute, and the company's legal representative and general manager, Xiu Jie, was also placed under consumption restrictions. In addition, on August 18, 2026, the Tonghua City Urban Management Administrative Law Enforcement Bureau determined that the company had carried out construction without planning approval procedures and imposed a fine of 260,000 yuan.

Impact on assets 2

Off-coverage companies 2

修正药业集团 (Xiuzheng Pharmaceutical Group)i
Private▼ NegativeRegulationrelevance

Xiuzheng Pharmaceutical Group faces court enforcement filings totaling 97.3 million yuan, a consumption restriction order against its general manager Xiu Jie, and a 260,000 yuan fine for unapproved construction.

吉林修检堂健康科技有限公司i
Private▼ NegativeRegulationrelevance

Jilin Xiujiantang Health Technology, an affiliated company of Xiuzheng Pharmaceutical, was hit with a single enforcement target of 92.6 million yuan.